What is a dose of ecstasy?

Becker S , Daumann J , Pelz S , Tuchtenhagen F , Bogusz M , Kock R , Gouzoulis-Mayfrank E (2001) Neuroendocrine probes as an index of central serotonergic neurotoxicity in ecstasy users: cannabis use is an important interfering variable. World J Biol Psychiatry 2: P015–P020

Bolla K I , Cadet J-L , London E D (1998) The neuropsychiatry of chronic cocaine abuse. J Neuropsychiatry Clin Neurosci 10: 280–289

Broocks A , Meyer T , George A , Hillmer-Vogel U , Meyer D , Bandelow B , Hajak G , Bartmann U , Gleiter C H , Rüther E (1999) Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners. Neuropsychopharmacology 20: 150–161

Buydens-Branchley L , Branchley M , Fergeson P , Hudson J , McKermin C (1997) Hormonal, psychological, and alcohol craving changes after m-chloropiperazine administration in alcoholics. Alcohol Clin Exp Res 21: 220–227

Buydens-Branchley L , Branchey M , Hudson J , Rothman M , Fergeson P , McKernin C (1999) Serotonergic function in cocaine addicts: prolactin responses to sequential D, L-fenfluramine challenges. Biol Psychiatry 45: 1300–1306

Fox H C , Parrott A C , Turner J J D (2001) Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 15: 273–281

Giancola P R , Moss H B , Martin C S , Kirisci L , Tarter R E (1996) Executive cognitive functioning predicts reactive aggression in boys at high risk for substance abuse: a prospective study. Alcohol Clin Exp Res 20: 740–744

Haney M , Ward A S , Gerra G , Foltin R W (2001) Neuroendocrine effects of d-fenfluramine and bromocriptine following repeated smoked cocaine in humans. Drug Alcohol Depend 64: 63–73

Luus C A E , Wells G L (1994) The malleability of eyewitness confidence: Co-witness and perseverance effects. J Appl Psychol 79: 714–723

Lyvers M (2000) ‘Loss of control’ in alcoholism and drug addiction: a neuroscientific interpretation. Exp Clin Psychopharmacol 8: 225–249

Milroy C M , Clark J C , Forrest A R W (1996) Pathology of deaths associated with ‘ecstasy’ and ‘eve’ misuse. J Clin Pathol 49: 149–153

Ornstein T J , Iddon J L , Baldacchino A M , Sahakian B J , London M , Everitt B J , Robbins T W (2000) Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsycho-pharmacology 23: 113–126

Page R A , Handley G W (1993) The effect of preventative measures in reducing after effects to hypnosis. Am J Clin Hypnosis 36: 26–37

Parrott A C , Sisk E , Turner J J D (2000) Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend 60: 105–110

Rainville P , Duncan G H , Price D D , Carrier B , Bushnell M C (1997) Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 277: 986–971

Ramsey J D , Butcher M A , Murphy M F , Lee T , Johnston A , Holt D W (2001) A new method to monitor drugs at dance venues. BMJ 323: 603-603

Reilley R R , Rodolfa E R (1981) Concentration, attention and hypnosis. Psychol Reports 48: 811–814

Reneman L , Booij J , de Bruin K , Reitsma J B , de Wolff F A , Gunning W B , den Heeten G J , van den Brink W (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864–1869

Rinne T , Westenberg H G M , den Boer J A , van den Brink W (2000) Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biol Psychiatry 47: 548–556

Sherlock K , Wolff K , Hay A W M , Conner M (1999) Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accident Emerg Med 16: 194–197

Spanos N P (1989) Experimental research on hypnotic analgesia. In Spanos N P , Chaves J F (eds), Hypnosis: the cognitive-behavioral perspective. Prometheus, New York

Spanos N P , Jones B , Malfara A (1982) Hypnotic deafness: Now you hear it – now you still hear it. J Abnorm Psychol 90: 75–77

World Health Organization (1997) Amphetamine-type stimulants. A report from the WHO meeting on amphetamines, MDMA and other psychostimulants, Geneva, 12–16 November 1996. WHO, Geneva

Yatham L N , Steiner M (1993) Neuroendocrine probes of serotonergic function: a critical review. Life Sci 53: 447–463

Zhou D , Huether G , Wiltfang J , Hajak G , Rüther E (1996) Serotonin transporters in the rat frontal cortex: lack of circadian rhythmicity but down-regulation by food restriction. J Neurochem 67: 656–661